Abbott Labs’ proposed $5.8bn acquisition of Alere will give its IVD sales a significant boost and propel the company up the ranks to become the sector’s No. 2, behind Roche.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?